Continuing Education Course Descriptions
The Continuing Education Program offers a wide range of courses that cover
state-of-the-art knowledge in toxicology, as well as new developments in toxicology
and related disciplines. Courses can be applied toward certifying and licensing
board requirements and may also be used for recertification with the American
Board of Toxicology (ABT). Both basic and advanced course topics are offered.
The basic course is intended to provide a broad overview of an area or to assist
individuals in learning new techniques or approaches. The advanced course is
intended to be of interest to individuals with previous knowledge of the subject
or already working in the field.
Please Note: Each Continuing Education Course
is offered in one of three time blocks: Sunrise (7:00 AM–7:45 AM), AM
(8:15 AM–12:00 NOON) or PM
(1:15 PM–5:00 PM). Registration for the Annual Meeting is required.
*The
Primary Specialty Section (SS) or Regional Chapter (RC) Endorser
SR01 – Use of Genome Databases for Toxicology
Sunrise Mini-Course
Chairperson: William B. Mattes, Gene Logic Inc, Gaithersburg, MD
Endorsements
Mechanisms Specialty Section
National Capital Area Chapter
Molecular and genomic information is increasingly an important part of all
biological research including toxicology. While toxicologists often focus on
data from microarray-based expression profiles, other molecular data, including
the organization and function of genes in the context of the cell, the physical
genome and sequence, and the relationships between species in terms of this
organization, can provide important insights. Therefore facilities with public
molecular biology databases and search tools is essential to all toxicologists.
Moreover, the recent availability of complete genomes, including the human,
mouse and rat, has made genome-wide queries and comparative genomics readily
accessible to all researchers and has the potential to revolutionize medical
research and practice. The largest public repository of biological sequence
information is maintained by the National Center for Biotechnology Information
(NCBI) at the National Library of Medicine. This course will describe the molecular
database resources, including sequences, structures and genomes, and the tools
available through the WWW interface to the NCBI. The discussion will then focus
on using these tools and databases as well as the specialized genomic resources.
The Entrez and BLAST Web services will be demonstrated and how both can be
used as a biological discovery system in toxicology will be illustrated. This
tutorial is intended as an overview and introduction of NCBI genomic and molecular
databases to toxicologists, but even experienced users will find it helpful.
Use of Genome Databases for Toxicology
Peter S. Cooper, NCBI User Services, National Library of Medicine, Bethesda,
MD
AM02/PM08 - Targeted Therapeutic Approach to Anti-Cancer Drug Development
ADVANCED
Chairperson(s): Vijayapal Reddy, Eli Lilly & Company, Greenfield, IN and
Myrtle A. Davis, Eli Lilly & Company, Greenfield, IN
Endorsements
Comparative and Veterinary Specialty Section
*Regulatory and Safety Evaluation Specialty Section
Over the past decade, a range of targeted anti-cancer drugs have been developed
that are designed to interfere with one or more of the many molecular mechanisms
that drive tumor growth. The molecularly-targeted approach to the development
of these new anti-cancer drugs has created a false impression that these newer
drugs, unlike earlier cytotoxic anti-cancer drugs, will be non-toxic. Cytotoxic
drugs are typically administered in short courses of maximal doses (MTD). This
is not necessarily appropriate for targeted therapies, which can require long-term
therapy and for which it is often difficult to determine the biologically most
effective dosage (BED). This course will focus on different aspects of regulatory,
preclinical, and clinical targeted anti-cancer drug development. The first
speaker will focus on tumor cell biology and the respective cell signaling
pathways that
hold promise for targeted anti-cancer therapy. The second speaker will present
differences in preclinical development philosophy between cytotoxic and targeted
anti-cancer drugs. The third speaker will discuss specific examples of preclinical
development of targeted biotherapeutics. The fourth speaker will discuss biomarkers
as endpoints of clinical efficacy and safety assessment. The final speaker
will focus on regulatory considerations of preclinical development of targeted
therapies,
highlighting differences between cytotoxic and targeted therapies. This advanced
course in drug development is targeted to government, biotechnology and pharmaceutical
toxicologists as well as general toxicologists with an interest in cancer chemotherapy.
Identification, Pharmacologic Expectations and Toxicological Considerations
for Targeted Therapies
Myrtle Davis, Eli Lilly & Company, Greenfield, IN
The Development of Cytotoxics to MTD and Targeted Drugs to BEDs: Is this the
Correct Paradigm?
Joseph E. Tomaszewski, National Cancer Institute, Rockville, MD
Preclinical Safety Evaluation of Anti-Cancer Biotherapeutics
Joseph Beyer, Toxicology & Pathology, Genetech, Inc, South San Francisco,
CA
Targeted Efficacy and Targeted Toxicity: Are the Biomarkers the Same?
Kerry L. Blanchard, Eli Lilly & Company, Greenfield, IN, USA
Regulatory Considerations for Nonclinical Development of Anti-cancer Drugs
John K. Leighton, U.S. Food and Drug Administration, Rockville, MD
AM03/PM09 – Reproductive Toxicity Testing: Study Designs, Evaluation,
Interpretation and Risk Assessment
BASIC
Chairperson: Donald G. Stump, WIL Research Laboratories, LLC, Ashland, OH
Endorsements
Regulatory and Safety Evaluation Specialty Section
*Reproductive and Developmental Toxicology Specialty Section
Risk Assessment Specialty Section
This course is intended to provide a general overview for scientists responsible
for the design, conduct and monitoring of reproductive toxicity studies. The
course will focus on reproductive biology, study design considerations, reproductive
endpoints, data interpretation and use of data in risk assessment. Reproductive
toxicity studies are among the most complex and challenging studies in the
field of toxicology. The studies assess multiple interrelated endpoints of
male and
female reproductive function. In order to properly design, conduct and interpret
these studies, a fundamental knowledge of male and female reproductive system
development, anatomy, physiology, and endocrinology are required. This course
will discuss the designs of reproductive studies for regulatory submission.
Individual lectures will discuss the anatomy and physiology of the male and
female reproductive
systems as well as endocrine regulation of these systems. Evaluation of toxicity
endpoints to assess male and female reproductive function will also be discussed
including mating, fertility, estrous cyclicity, spermatogenesis, sexual behavior,
parturition, reproductive hormone analysis, nesting and nursing behavior, reproductive
organ weights and histopathology, and proper use of statistical analysis. The
course will conclude with discussions on some common issues related to reproductive
toxicity testing, interpretation of results, and how these results are ultimately
used to assess potential risks to human reproduction. In summary, this course
will present the key information required for the design of reproductive toxicity
studies and interpretation of reproductive toxicity data and provide guidance
for use of the data for risk assessment of human reproduction.
Reproductive Toxicity Testing: Study Designs and General Considerations
Barry S. McIntyre, Schering Plough Research Institute, Lafayette, NJ
Male Reproduction: Biology and Toxicity Endpoints
Kok Wah Hew, Purdue Pharma LP, Ardsley, NY
Female Reproduction: Biology and Toxicity Endpoints
Christopher J. Bowman, WIL Research Laboratories, LLC, Ashland, OH
Reproductive Toxicity Testing: Data Interpretation and Risk Assessment
Rochelle W. Tyl, RTI International, Research Triangle Park, NC
AM04 - Predictive Power of Novel Technologies (Cells to 'Omics'): Promises,
Pitfalls and Potential Applications
BASIC
Chairpersons: Srikanth S. Nadadur, USEPA, Research Triangle Park, NC and Mary
Jane Cunningham, Houston Advanced Research Center, The Woodlands, TX
Endorsements
*Inhalation Specialty Section
Molecular Biology Specialty Section
Toxicologic & Exploratory Pathology Specialty Section
Abstract Body: Advances in the disciplines of cell and molecular biology have
led to the development of novel biotechnologies capable of generating “global
molecular profiles” for in situ toxicological assessment. These technologies
should accelerate our understanding of molecular basis for potential toxicity
and susceptibility. This course will provide both theoretical and practical information
on these emerging high throughput technologies, their applicability, interpretation
and integration to gain a more comprehensive understanding of cellular responses
to chemical/toxicant stress. The first presentation will cover the potential
utility of Laser Capture Micro-Dissection in isolating specific cell populations
for toxicological assessment at the level of RNA and proteins. The second presentation
will provide the ongoing evolution of gene expression profiling approaches from “toxicogenomics” to
systems biology. The third presentation will provide an overview of proteomic
technologies in analyzing the protein interactions and downstream signaling
mediators involved in toxic response pathways. The final presentation will
examine the
capabilities of high throughput technologies in identifying the single nucleotide
polymorphisms (SNPs) and their predictive value for characterizing underlying
genetic susceptibilities to toxicants. Overall the course is aimed at educating
toxicologists on the array of new technologies available to research toxic
outcomes and their underlying mechanisms. The goal is to move towards a better
and reliable
prediction and extrapolation of toxic responses. This course will also serve
as a refresher course for scientists, technical and regulatory staff involved
in various stages of compound development or regulation.
Integrating Transgenic Animal Models and Laser Capture Microdissection Applications
with 'Micro-omic'-Based Analyses For In Vivo Toxicological Assessments
Kevin L. Dreher, NHEERL, USEPA, Research Triangle Park, NC
Gene Expression Profiling for Toxicity Assessment using Systems Biology
Mary Jane Cunningham, Houston Advanced Research Center, The Woodlands, TX
Clinical Proteomics: Mapping Molecular Networks in Clinical Specimens using
Reverse Phase Protein Microarrays
Emanuel F. Petricoin, George Mason University, Manasas, VA
Common DNA Variation in Human Disease and Drug Response
Steven Hamilton, University of California, San Francisco, San Francisco,
CA
AM05 - Comparative Endocrine Toxicology
BASIC
Chairpersons: Stephen B. Hooser, Purdue University, West Lafayette, IN and
Charles C. Capen, The Ohio State University, Columbus, OH
Endorsements
*Comparative and Veterinary Specialty Section
Reproductive and Developmental Toxicology Specialty Section
Toxicologic & Exploratory Pathology Specialty Section
Hormones secreted by cells of the endocrine system have diverse effects throughout
the body. Exposure to xenobiotic compounds can result in profound changes
to the endocrine organs and/or their target cells. Significant species differences
exist in the structure and function of endocrine and reproductive organs
making interpretation of test results and extrapolation from animal models
to humans more challenging. In addition to the numerous anatomical and physiological
differences, there are also species variations in metabolism and response
to toxicants. It is the goal of these presentations to give an overview of
the structure, function, regulation, and toxic responses of selected endocrine
and reproductive organs. In addition, the speakers will discuss the hormonal
assays and other mechanistic approaches necessary to make species comparisons,
and to extrapolate the findings from animals to humans. Each presentation
will briefly describe important species differences with regard to anatomy,
endocrine physiology, and response to different classes of xenobiotic chemicals
by selected endocrine and reproductive organs such as the thyroid (follicular
cells), ovary, and testis (Leydig cells). One presentation will focus on
the principles and pitfalls of hormonal measurements in laboratory animals
considering advantages/disadvantages of different methods, species specificity
of certain assays, most appropriate sampling times, and other useful items
to consider in future protocol development. Following completion of this
workshop, attendees should have a more complete understanding of the comparative
endocrinology and toxicology of selected endocrine and reproductive organs
in laboratory animals.
Comparative Endocrine Toxicology of the Thyroid Gland
Charles C. Capen, The Ohio State University, Columbus, OH
Comparative Ovarian Toxicology
Jodi Flaws, University of Maryland, Baltimore, MD
Comparative Endocrinology and Toxicology of Testicular Leydig Cells
Jon C. Cook, Pfizer, Inc., Groton, CT
Principles and Pitfalls of Hormone Measurements in Toxicology Studies
Terry M. Nett, Colorado State University, Fort Collins, CO
AM06 - Essentials of Metal Toxicology
BASIC
Chairpersons: Wei Zheng, Purdue University, West Lafayette, IN and Michael
P. Waalkes, NIEHS, Research Triangle Park, NC
Endorsements
Mechanisms Specialty Section
*Metals Specialty Section
Neurotoxicology Specialty Section
Risk Assessment Specialty Section
Metals are ubiquitously present in environment, essential to human health,
and yet toxic upon overexposure. They are neither synthesized by living matter
nor destroyed by human endeavour. Metals play a significant role in many human
diseases. Unique physical, chemical and biological properties allow metals
to persist in the body, cause long-lasting effects, and yet leave few choices
for therapeutic intervention. A fundamental question remains, namely what makes
metals toxic in promoting carcinogenesis, neurotoxicity, reproductive, liver
and kidney injuries, or generalized metabolic disease? This basic course is
intended to address the essentials in metal toxicology by providing cutting-edge
knowledge on the concepts, theories, clinical outcome, and research methodologies
in metal toxicology. The first lecture will highlight the clinical symptoms
of metal-induced human diseases, common routes of exposure, and therapeutic
intervention. Two subsequent lectures will address metal pharmacokinetics and
the general mechanisms of metal-induced cell death, specifically apoptosis.
The final lecture will discuss animal models, based on either symptomatic outcomes
or biochemical consequences, for studying metal toxicities. Speakers will address
these essentials by providing details specific to “hot” metals,
such as arsenic, mercury, manganese, lead, and uranium. The course will serve
as an introduction to those who desire an expanded knowledge on essentials
of metals in human health and diseases, essentials of toxicological actions
of metals, and essentials of research approaches in metal toxicological investigation.
The course will also be of interest to others engaged in wider aspects of carcinogenesis,
neurotoxicology, risk assessment, and occupational health.
Metals in Human Diseases: Symptoms and Clinical Intervention
Howard Hu, Harvard University, Boston, MA
Distribution of Metals: Role of Metal Transporters and Selectivity of Disposition
Michael Aschner, Vanderbilt University, Nashville, TN
Molecular Mechanism of Metal Toxicity: Signal Transduction and Oxidative Stress
Anumantha Kanthasamy, Iowa State University, Ames, IA
Animal Models Used in Metal Toxicological Research
Tomas Guilarte, Johns Hopkins University, Baltimore, MD
AM07 - Practical Strategies for Evaluation of Immunosuppression in Pharmaceutical
Development
BASIC
Chairperson: Brian G. Short, Allergan, Inc, Irvine, CA
Endorsements
Immunotoxicology
Regulatory and Safety Evaluation
*Toxicologic & Exploratory Pathology
Increased focus has been placed on evaluating immunotoxicity, particularly
immunosuppression, in pharmaceutical development of small molecules and biologics
following recent issuance of regulatory guidelines from FDA and CPMP and current
ICH discussions on harmonization. Toxicologists, pathologists, immunologists
and clinicians in the drug industry are faced with the challenge of addressing
the intent of the current guidance documents in a scientifically valid and
responsible manner. An integrated approach is necessary to provide a weight
of evidence for signal detection in routine toxicity studies as well as conducting
immunotoxicity studies or adding endpoints in routine toxicity studies to assess
immunophenotyping or functional immune alterations. The toxicologist is also
central in communicating the risk to clinicians and regulators following interpretation
of nonclinical immunotoxicology data and participating in the search for clinical
immune biomarkers to ensure clinical safety of trial participants. The goal
of this course is to discuss regulatory guidance and use case examples to illustrate
the integration of toxicology, pathology and immunology in addressing both
recent scientific advances and practical approaches in the pharmaceutical company
setting and how this knowledge impacted clinical trials and labeling, with
a focus on drug-induced immunosuppression. Similarities and differences in
FDA and CPMP immunotoxicity guidance documents and recent progress in ICH harmonization
will be discussed. Signal detection, including data from standard toxicity
studies and the controversies among toxicologists and pathologists in following
the guidelines will be addressed, including the recently drafted Best Practice
Guideline for the Routine Pathology of the Immune System by the STP Immunotoxicology
Working Group. Immunophenotyping conducted by flow cytometry or lymphoid immunohistochemistry
will cover recent advances with case studies. Functional assays, such as T-cell
dependent antibody response, natural killer cell activity, host resistance
macrophage/neutrophil function, and cell-mediated immunity will be discussed
with regard to design and timing in drug development from an immunotoxicologists
perspective. Finally, interpretation of nonclinical immunotoxicology data for
risk assessment in clinical trials and use of clinical immune biomarkers will
be featured.
Immunotoxicology: What’s New on the ICH Harmonization Front
Kenneth L. Hastings, CDER Office of New Drugs, USFDA, Rockville, MD
Immunosuppression Signal Detection in Standard Toxicity Studies and
Immunophenotyping: A Pathologist’s Approach
Patrick J. Haley, AstraZeneca, Wilmington, DE
Assay to Assay: Functional Evaluation of Imunosuppression
Danuta J. Herzyk, GlaxoSmithKline, King of Prussia, PA
Clinical Viewpoint: Interpretation of Nonclinical Immunotoxicity Data, Human
Risk Assessment and Clinical Immune Biomarkers
Ian Gourley, Lilly Research Laboratories, Indianapolis, IN
PM10 - Functional Analysis of Gene and Protein Expression: From Experimental
Design to Data Analysis
ADVANCED
Chairperson: Richard S. Pollenz, University of South Florida, Tampa, FL
Endorsements
Mechanisms Specialty Section
The mechanistic analysis of cellular responses to xenobiotics requires the
functional characterization of changes in both gene and protein expression.
The ability to study changes to both genes and proteins in vitro and in vivo
has become accessible to more laboratories with the development of molecular
tools such as microarrays, siRNA, recombinant protein expression and viral
gene delivery. However, the ability to utilize these techniques and generate
reproducible results requires a detailed understanding of each procedure. Thus,
the goal of this course is to provide the investigator with an overview of
experimental design and the use of proper controls for four cutting edge techniques.
The first talk will focus on experimental design and analysis of gene expression
studies utilizing microarrays. The second presentation will discuss recent
advances in the chomatin-immunoprecipitation (ChIP) assay for the analysis
of protein interactions at the level of DNA. The third presentation will discuss
gene delivery into hepatocytes in vivo utilizing the adenovirus system. Finally,
the last presentation will discuss the advantages and disadvantages of recombinant
protein expression in cultured cells with emphasis on the level and functionality
of the expressed protein and the use of siRNA. The course will be of broad
interest to those laboratories considering contemporary mechanistic approaches
to gene and protein expression as well as those currently investigating these
endpoints.
Design and Analysis of Microarray Experiments
Thomas Sutter, Feinston Center for Genomic Research, University of Memphis,
Memphis, TN, USA
Analysis of Protein_DNA Interactions Using Chromatin_Immunoprecipitation (ChIP)
Eli Hestermann, Department of Biology, Furman University, Greenville, SC, USA
Adenovirus_Mediated Gene Delivery to Alter Protein Expression In Vivo
Cornelis Elferink, Department of Pharmacology, UTMB, Galveston, TX, USA
Basics of Recombinant Protein Expression and RNA Interference in Cultured Cells
Richard S. Pollenz, Department of Biology, University of South Florida, Tampa,
FL, USA
PM 11 - Xenobiotic Transporters
BASIC
Chairperson: Douglas A. Keller, Sanofi-Aventis
Endorsement
*Drug Discovery Specialty Section
Toxicologists have traditionally considered that chemicals are absorbed and
distributed throughout the body largely due to their lipid solubility and diffusivity
through cell membranes. We also consider drug metabolism as a process that
makes chemicals more water soluble so they will less readily pass cell membranes
and be more rapidly excreted. However, it was not understood how the water-soluble
metabolite could exit the cell to be excreted. During the last decade a number
of transporters have been identified that not only are responsible for the
excretion of chemicals, but also for the absorption and distribution of xenobiotics.
This course, highlighting the progress made in this research field as both
timely and of significant interest to a large number of SOT members who are
in academic, government and industrial sectors. This course will give an overview
of the families of transporters involved in absorption, distribution and excretion
of drugs and chemicals, as well as presentations specific to the major tissues
where transporters are known to influence toxicity. The roles of transporters
in disposition and toxicity in the liver, kidney, intestine and brain will
be discussed.
Overview of the Families of Transporters Responsible for the Absorption, Distribution,
and Excretion of Drugs
Curtis D. Klaassen, University of Kansas Medical Center, Kansas City, KS
Pharmacological and Toxicological Significance of Hepatic Transporters
Bruno Hagenbuch, University of Kansas Medical Center, Kansas City, KS
Importance of Renal Transporters in Chemical Disposition and Toxicity
John B. Pritchard, NIEHS, Research Triangle Park, NC
Clinical and Pharmacological Implications of Transporters in the Intestine
and Blood-Brain Barrier
Jashvant D. Unadkat, University of Washington, Seattle, WA
PM12 - Neuropathology for the Toxicologist
BASIC
Chairperson: David C. Dorman, CIIT Centers for Health Research, Research Triangle
Park, NC
Endorsements
Comparative and Veterinary Specialty Section
Neurotoxicology Specialty Section
*Toxicologic & Exploratory Pathology Specialty Section
This course is designed to provide a basic overview of rodent neuropathology.
The course will start off with a review of the normal anatomy and histology
of the adult nervous system. This overview will also discuss the ways in
which neuropathology and functional assays of motor activity and other
behaviors
relate to one another. The second lecture relates to tissue handling techniques
and basic approaches in neuropathology. This topic is critically important
since the ability to detect chemical-induced neuropathology requires proper
tissue fixation and processing. Although the second lecture will largely
focus on rodent tissues, the approaches and methods to be discussed can
be easily
adapted to other species. The course will then transition into two presentations
focused on common lesions induced by model neurotoxicants. One presentation
will focus on central nervous system effects while the latter lecture will
address peripheral neuropathies. Our final presentation will discuss morphometric
approaches in neuropathology including a discussion of the use of magnetic
resonance imaging methods in neurotoxicologic pathology. Participants in
this course will gain a greatly improved appreciation of basic neuropathology
and
applications to toxicology.
An Introduction to the Nervous System
David C. Dorman, CIIT Centers for Health Research, Research Triangle Park,
NC
Practical Methods in Rodent Neuropathology
Mark T. Butt, Pathology Associates, Frederick, MD
Oh, My Aching Head: Toxicant-Induced Neuropathology of the Central Nervous
System
Brad Bolon, GEMpath Inc., Cedar City, UT
Morphologic Assessment of the Peripheral Nervous System
William M. Valentine, Vanderbilt University, Nashville, TN
Quantitative Morphology in Rodent Neuropathology
Karl Jensen, USEPA, Research Triangle Park, NC
PM13 - Assessing Airway Injury and Remodeling Induced by Inhaled Pollutants
Using Magnetic Resonance Imaging, Microscopy and Modeling
BASIC
Chairpersons: Jack R. Harkema, Michigan State University, East Lansing, MI
and Richard Corley, Pacific Northwest National Laboratories, Richland, WA
Endorsements
Inhalation Specialty Section
The goal of this course is to present state-of-the-art methods of assessing
injury and remodeling of the conducting airways caused by acute or chronic
exposures to airborne toxicants including environmental pollutants (e.g.,
particulate matter, ozone, cigarette smoke, fungal and bacterial toxins).
The nature, severity
and distribution of airway lesions caused by these inhaled toxicants are
due to an integration of several factors including the physicochemical
characteristics of the inhaled toxicant (e.g., size of the particles, reactivity
of the gas),
the exposure regimen (e.g., short-versus long-term, continuous versus episodic),
local intra-airway dosimetry (e.g., hot spots of deposition at airway bifurcations,
slow clearance from sites of overload) and cellular susceptibility (e.g.,
sensitive
versus resistant epithelial cell types). Toxicant-induced alterations to
the airway structure range from oncotic or apoptotic cell death of epithelial
cells
lining the luminal surface with concurrent acute inflammation to marked
remodeling of the airway wall due to intramural fibrosis, epithelial hyperplasia/metaplasia,
and chronic active inflammation. The strengths and limitations of a variety
of state-of-the-art imaging techniques for visualizing macroscopic changes
to the respiratory tract, including magnetic resonance imaging, and computed
tomography, will be presented along with those of more routine methods
of
light, electron and confocal microscopy for assessing tissue and cellular
pathology
caused by inhaled pollutants. The fundamental principles of airway stereology
will also be presented and how these mathematically proven morphometric
techniques may be used to quantify, without bias, changes to these tubular
structures
in order to estimate severity of complex lesions. Finally, presenters will
describe the development and implementation of computational models of
geometrically correct upper and lower airways used to define, site-specific,
dose-response
relationships along the respiratory tract of laboratory animals and to
estimate the risk of air pollutant exposures to human health.
An Overview of Airway Injury and Remodeling Caused by Inhaled Toxicants:
From the Nose to the Lung and from Gases to Particles
Jack R. Harkema, Michigan State University, East Lansing, MI
State-of-the-Art Techniques for Imaging the Upper and Lower Respiratory
Tract: Identifying macroscopic to microscopic airway alterations caused
by airborne
toxicants
Charles Plopper, University of California-Davis, Davis, CA
Sampling, Stereology, and Statistics: Quantifying changes along tubular
structures and without bias
Dallas Hyde, University of California-Davis, Davis, CA
Using Computer-Assisted Airway Reconstruction to Define Dose-Response
Relationships
Julia Kimbell, CIIT Centers for Health Research, Research Triangle
Park, NC
Download Course Descriptions
|